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A sensitive, speciﬁc and fast method to quantify 3a-hydroxytibolone in human plasma using deuterated
3a-hydroxytibolone (d5) as internal standard is described. The analyte and the internal standard were
extracted from plasma (900 mL) by liquid-liquid extraction using ethyl ether/hexane (50/50, v/v) and
ammonium hydroxide (50%). The extracts were analyzed by high performance liquid chromatography
coupled to electrospray ionization tandem mass spectrometry without derivatization. Chromatography
was performed isocratically on a Gemini-NX™ C18 5 mm (150  4.6 mm i. d.) column. The method had a
chromatographic run time of 3.75 min and a linear calibration curve over the range 1e100 ng/mL. The
limit of quantiﬁcation validated was 1 ng/mL. This method was used to assess the bioequivalence be-
tween two different tibolone oral formulations: Livolon (1.25 mg tablet) provided by Biolab Sanus
Farmace^utica (Brazil), as the test formulation, and Libiam™ (1.25 mg tablet) produced by Libbs Farm-
ace^utica (Brazil), as the reference formulation. A single 3.75 mg dose of each formulation was admin-
istered to 46 postmenopausal female healthy volunteers. The study was conducted in an open,
randomized, two-period crossover balanced design with a 2 week washout interval between the doses.
The 90% conﬁdence interval for Cmax, AUC(0-last) and AUC(0-inf) individual test/reference ratios were 97.48
e111.51, 95.35e103.20 and 96.42e103.86, respectively. It is concluded that Livolon (1.25 mg tablet) is
bioequivalent to Libiam™ (1.25 mg tablet), with regards to both rate and extent of absorption.
© 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tibolone [(7a,17a)-17-hydroxy-7-methyl-19-norpregn-5 (10)-
en-20-yn-3-one] is a synthetic steroid with estrogenic, progesto-
genic and androgenic effects. It has been widely used as an alter-
native to estrogen replacement therapy for almost two decades,
mainly to treat postmenopausal symptoms (e.g., hot ﬂushes,
insomnia, headache, fatigue, mood swings and decreased libido)
and prevent osteoporosis. A daily dose of 2.5 mg is often recom-
mended but lower doses such as 1.25 mg are also used [1,2].-170, Campinas, SP, Brazil.
ito).
n open access article under the CCAfter oral administration to postmenopausal women, tibolone is
rapidly converted into three active metabolites: 3a-hydrox-
ytibolone (predominant metabolite), 3b-hydroxytibolone and D4-
tibolone. The metabolism occurs in liver and intestine as well as in
tibolone target tissues. The 3-hydroxy metabolites are present in
the blood circulation predominantly in their inactive form (sul-
phate conjugates). The plasma levels of tibolone and the D4-isomer
are very low [3]. Bioequivalence studies are based on the quanti-
ﬁcation of 3a-hydroxytibolone in plasma, as recommended by
regulatory agencies, since it is the predominant activemetabolite of
tibolone [4,5].
The objective of this study was to develop a sensitive, speciﬁc
and fast high performance liquid chromatography (HPLC) coupledBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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MS) method to quantify 3a-hydroxytibolone in human plasma
using deuterated 3a-hydroxytibolone (d5) as internal standard
(I.S.), without derivatization. The method was used in a bioequiv-
alence assay between two different tibolone oral formulations:
Livolon (1.25 mg tablet) provided by Biolab Sanus Farmace^utica
(Brazil), as the test formulation, and Libiam™ (1.25 mg tablet)
produced by Libbs Farmace^utica (Brazil), as the reference
formulation.
2. Materials and methods
2.1. Method development
2.1.1. Chemicals, reagents and blank human blood
Livolon, the tibolone test formulation, was provided by Biolab
Sanus Farmace^utica (Brazil), with lot number 4030497. Libiam™,
the tibolone reference formulation, was purchased from Libbs
Farmace^utica (Brazil), with lot number 13k0524. 3a-hydrox-
ytibolone was purchased from Toronto Research Chemicals (Can-
ada), with lot number 25-SSR-16-1 and purity of 97%. 3-
hydroxytibolone-d5 (a mixture of deuterated 3a and 3b isomers)
was purchased from Synﬁne Research (Canada), with lot number S-
1315-001A4 and purity of 98.6%. Acetonitrile (HPLC grade) and
methanol (HPLC grade) were purchased from Panreac (Spain). So-
dium hydroxide (Panreac, Spain), ammonium hydroxide (Synth,
Brazil), ethyl ether (Honeyhell, U.S.A.) and hexane (Honeyhell,
U.S.A) were of analytical grade. Ultra pure water was obtained from
a MilliQ™ system (EMD Millipore, U.S.A.).
Blank human blood was collected with the anticoagulant so-
dium heparin from healthy and drug-free volunteers. After centri-
fugation, blank human plasma was obtained, pooled and stored
at 20 C until used.
2.1.2. Calibration standard solutions and quality control samples
Stock solutions of 3a-hydroxytibolone and 3-hydroxytibolone-
d5 were prepared in methanol/water (70/30, v/v). Working solu-
tions were prepared by diluting stock solutions with acetonitrile/
water (50/50, v/v).
Calibration standard solutions were prepared by spiking blank
plasma with 3a-hydroxytibolone working solutions to give con-
centrations of 1, 2, 10, 20, 40, 60, 80 and 100 ng/mL. The calibration
standard solutions and blanks were daily prepared in duplicate for
each analytical batch.
Quality control (QC) samples were prepared by spiking blank
plasma with 3a-hydroxytibolone working solutions to give con-
centrations of 1, 3, 5, 30, 75 and 150 ng/mL, designated LOQ (limit of
quantiﬁcation), QCL (low concentration quality control), QCM 1
(medium concentration quality control 1), QCM 2 (medium con-
centration quality control 2), QCH (high concentration quality
control) and QCD (dilution quality control), respectively. The QCD
(used to evaluate the dilution integrity of the method) was diluted
in blank plasma (1:1) for analysis. QC samples were daily prepared
for each analytical batch.
The spiked plasma samples (calibration standards and quality
controls) were extracted from each analytical batch along with the
unknown samples.
2.1.3. Sample preparation
Brieﬂy, 900 mL of each plasma sample were introduced into a
glass tube with 50 mL of the 3-hydroxytibolone-d5 working solu-
tion (1000 ng/mL), 50 mL of ammonium hydroxide (50%) and 4 mL
of ethyl ether/hexane (50/50, v/v), sequentially and with 5 s of
vortex mixing in between. Then, the glass tube was vortex-mixed
for 60 s and frozen at e 80 C. The upper phase (organic phase)was transferred to another glass tube and dried with N2 at 40 C.
The dry residues were reconstituted with 120 mL of acetonitrile/
water (60/40, v/v) þ NaOH (2 mM) and vortex-mixed for 10 s. At
this point, the solutions were transferred to the CTC HST PAL™
auto-injector microvials (CTC Analytics, Switzerland).
2.1.4. Chromatographic conditions
The HPLC was performed in a Gemini-NX™ C18 5 mm
(150  4.6 mm i. d.) column (Phenomenex, U.S.A.) with a G1311A
pump (Agilent, Germany) at a ﬂow rate of 1150 mL/min. The mobile
phase (isocratic elution) was acetonitrile/water (60/40, v/
v) þ NaOH (2 mM). The column was operated at 60 C and the
pressure of the systemwas approximately 67 bar. The temperature
of the auto sampler was maintained at 8 C and the injection vol-
ume was 20 mL. Typical retention time was approximately 2.5 min
for both 3a-hydroxytibolone (analyte) and 3a-hydroxytibolone-d5
(I.S.) and the total run time was 3.75 min. The total ﬂow rate was
split in a 2:3 ratio (no more than 770 mL/min were directed to the
ESI source). The smooth factor of 5 was set for both analyte and I.S.
All chromatograms were integrated in the automatic mode by
Analyst™ software version 1.4.1 (Applied Biosystems, U.S.A.).
2.1.5. Mass-spectrometric conditions
The MS was performed in a API 4000™ mass spectrometer
(Applied Biosystems, U.S.A.) equipped with an ESI source using a
crossﬂow counter electrode run in positive ion mode with multiple
reaction monitoring (MRM). The mass spectrometer was set as
follows: 332.2 > 297.2 and 337.4 > 302.4 for 3a-hydroxytibolone
and I.S. as the precursor ions and the respective product ions (m/z).
The proposed fragmentation pathways are presented in Figs. 1 and
2. Full-scan mass spectrograms of 3a-hydroxytibolone and I.S. are
illustrated in Figs. 3 and 4, respectively. The source temperature
was set at 600 C and the ionspray voltage at 5.0 kV. For both an-
alyte and I.S., the dwell time and the optimized parameters of
declustering potential, collision energy and collision exit potential
were 0.4 s, 46 V,12 eV and 18 V, respectively. Datawere acquired by
Analyst™ software version 1.4.1 (Applied Biosystems, U.S.A.).
2.2. Method validation
Samples analyses were carried out in accordance with the bio-
analytical methods validation guidelines from the U.S. Food and
Drug Administration (F.D.A.) [4] and Brazilian National Health
Surveillance Agency (A.N.V.I.S.A.) [5].
2.2.1. Linearity
A linear least-squares regression with a weighting index of 1/x
was performed on the peak area ratios of 3a-hydroxytibolone and
I.S. vs. 3a-hydroxytibolone concentrations of the eight plasma
calibration standards (1, 2, 10, 20, 40, 60, 80 and 100 ng/mL) in
duplicate to generate the calibration curves. In addition, a blank
plasma sample (non-spiked) and a zero plasma sample (spiked only
with I.S.) were run in duplicate to demonstrate the absence of in-
terferences. Correlation coefﬁcient must be greater than 0.98.
2.2.2. Accuracy and precision
QC samples were used to evaluate the accuracy and precision of
the method. Accuracy was deﬁned as the percentage relative error,
RE (%) ¼ (E  T) (100/T), and precision as the relative standard
deviation, RSD (%) ¼ 100 (SD/M), where M is the mean, SD is the
standard deviation of M, E is the experimentally determined con-
centration and T is the theoretical concentration. Accuracy must be
between 85 and 115% of the nominal concentration and precision
must be less than 15% (except for LOQ, as described below; item
2.2.3).
Fig. 1. Proposed pathway for the fragmentation of 3a-hydroxytibolone (analyte).
Fig. 2. Proposed pathway for the fragmentation of 3a-hydroxytibolone-d5 (internal standard).
Fig. 3. Full scan mass spectra of 3a-hydroxytibolone (analyte).
L.A. Portela et al. / Analytical Chemistry Research 8 (2016) 16e25182.2.3. Selectivity and sensitivity
Blank normal plasma (n ¼ 4), blank lipemic plasma (n ¼ 2) andblank hemolyzed plasma (n ¼ 2) samples from different donors
were run during the pre-study validation to evaluate selectivity. No
Fig. 4. Full scan mass spectra of 3a-hydroxytibolone-d5 (internal standard).
L.A. Portela et al. / Analytical Chemistry Research 8 (2016) 16e25 19peaks at the retention times of the analyte and I.S were expected.
The LOQ validated was the lowest concentration at which both the
accuracy and precisionwere less than 20% and the analyte response
was at least 5 times the baseline noise.2.2.4. Carry-over and matrix effect
Blank normal plasma samples (n¼ 2) were run after an injection
of a QCH sample to evaluate carry-over. Carry over must be less
than 20% and 5% of the LOQ of the analyte and I.S., respectively. QCL
and QCH samples made from normal plasma (n ¼ 12 for each
concentration), lipemic plasma (n ¼ 6 for each concentration) and
hemolyzed plasma (n ¼ 6 for each concentration) were run to
evaluate matrix effect. Then, a factor matrix standard (FMS) was
obtained for each sample according to the following formula:
FMS ¼ (response of analyte in matrix/response of internal standard
in matrix)/(response of analyte in solution/response of internal
standard in solution). The precision of FMS must be less than 15%.2.2.5. Stability
QCL (n ¼ 3) and QCH (n ¼ 3) samples were subjected to three
freeze-and-thaw cycles (from 20 C to room temperature), short-
term (6:15 h at room temperature), long-term (thawed and
extracted to be tested after 186 days) and autosampler (63:30 h at
8 C) stability tests. Subsequently, the analyte concentrations were
measured in comparison with freshly prepared samples (n ¼ 3 for
each concentration) to obtain accuracy and precision.2.3. Bioequivalence study
2.3.1. Clinical protocol
The present method was used in a bioequivalence assay be-
tween two different tibolone oral formulations: Livolon (1.25 mg
tablet) provided by Biolab Sanus Farmace^utica (Brazil), as the test
formulation, and Libiam™ (1.25 mg tablet) produced by Libbs
Farmace^utica (Brazil), as the reference formulation. Forty-eight
postmenopausal female volunteers aged between 46 and 60 years
old and within 15% of the ideal body weight were selected for the
study. All volunteers were drug-free and healthy as assessed by
general physical examination, electrocardiogram and laboratory
tests (biochemical, hematological, serological and routine urinaly-
sis). All subjects provided written informed consent and the study
was conducted in accordance to the provisions of the Declaration of
Helsinki (1964) revisions [6].
The study was conducted in an open, randomized, two-period
crossover balanced design with a 2 week washout interval be-
tween the doses. During each period (approximately 36 h), the
volunteers were hospitalized at 6:00 p.m. having a standard eve-
ning meal between 7:00 and 9:00 p.m. After an overnight fast they
received at 7:00 a.m. a single 3.75 mg dose (3 tablets of 1.25 mg) of
either formulation with 200 mL of water. All volunteers were then
fasted for 2 h following the drug administration after which a
standard breakfast was consumed. A standard lunch and an eve-
ning meal were provided throughout the day. No other foods were
permitted during the in-house period. Signs, symptoms, arterial
pressure, heart rate and temperature were recorded just before and
every 4 h after drug administration. Blood samples (8 mL) from a
Fig. 5. Chromatogram at blank normal plasma (top channel: 3a-hydroxytibolone/bottom channel: internal standard).
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Table 1
Quality control samples accuracy and precision data from the pre-study validation (n ¼ 7 for each concentration/3 batches).* diluted in blank plasma (1:1) for analysis.
Nominal concentration (ng/mL)
1 3 5 30 75 150*
Intra-batch (n ¼ 7)
Mean 1.04 3.30 5.43 31.90 79.40 79.20
Range 0.80e1.24 3.02e3.67 4.85e5.82 31.30e32.60 77.30e83.00 76.50e82.80
Accuracy (%) 104.40 110.00 108.50 106.20 105.90 105.60
Precision (%) 13.20 7.10 7.50 1.60 2.60 3.00
Inter-batch (n ¼ 21)
Mean 0.97 3.07 5.07 30.50 76.30 75.10
Range 0.70e1.26 2.72e3.67 4.51e5.82 27.30e32.60 69.10e83.00 69.00e82.80
Accuracy (%) 97.90 102.40 101.30 101.80 101.70 100.10
Precision (%) 14.70 7.70 8.20 5.50 4.90 5.20
L.A. Portela et al. / Analytical Chemistry Research 8 (2016) 16e25 21suitable antecubital vein were collected in sodium heparin con-
taining tubes before and after 0.25, 0.5, 0.75, 1, 1.25, 1,5, 1.75, 2, 2.33,
2.66, 3, 3,33, 3.67, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 14, 16, 18 and 24 h after
the administration of each tibolone formulation. After centrifuga-
tion of the blood, plasma was obtained and stored at 20 C until
used.2.3.2. Pharmacokinetics and statistical analysis
The bioequivalence between the two formulations of tibolone
was assessed by calculating individual test/reference ratios for the
peak plasma concentration (Cmax), the area under the curve (AUC)
of the plasma concentration until the last concentration observed
(AUC(0-last)) and the area under the curve of the plasma concen-
tration between the ﬁrst sample and inﬁnity (AUC(0-inf)). The Cmax
and the time taken to achieve this concentration (Tmax) were ob-
tained directly from the curves. The AUC(0-last) was calculated by
applying the linear trapezoid rule. Extrapolation of this area to
inﬁnity (AUC(0-inf)) was done by adding the value Clast/ke to the
calculated AUC(0-last). The ﬁrst-order terminal elimination rate
constant (ke) was estimated by linear regression from the points
describing the elimination phase in a log-linear plot, and the half-
life (t1/2) was derived from this rate constant (t1/2 ¼ ln (2)/ke).
The Cmax and AUC data for the two tibolone formulations were
analyzed by ANOVA to determine whether the 90% CI (conﬁdence
interval) of the individual test/reference ratios was within the
80e125% interval indicative of bioequivalence.3. Results
3.1. Method validation
Blank normal plasma, blank lipemic plasma and blank hemo-
lyzed plasma samples were run during the pre-study validation and
there were no interferences at the retention times of the analyte or
I.S. Fig. 5 shows a chromatogram at blank normal plasma. The
method was a linear regression for 3a-hydroxytibolone concen-
trations from 1 to 100 ng/mL (correlation coefﬁcient ranged from
0.9991 to 0.9994). QC samples intra and inter-batch accuracy and
precision from the pre-study validation are summarized in Table 1.
The LOQ validated was 1 ng/mL.
Fig. 6 shows a chromatogram at the LOQ. Although a mixture of
3a and 3b-hydroxytibolone-d5 was employed as internal standard,
these metabolites have different chemical and physical properties
since they are diastereomers [7]. In RP chromatography, 3a-
hydroxytibolone-d5 is more polar [8], eluting earlier (retention
time at 2:51 min) than 3b-hydroxytibolone-d5 (retention time at
2.86 min). Indeed, in the analyte channel the ﬁrst peak was present
in most of the samples whereas the later peak appeared only near
the Tmax, indicating that the ﬁrst peak is related to 3a-hydroxytibolone, which has been reported as the predominant
circulating metabolite of tibolone [3,7,8].
Carry-over evaluation shown no peaks of analyte or I.S in the
chromatograms of blank normal plasma samples run after an in-
jection of a QCH sample (Fig. 7). No signiﬁcant matrix effect was
observed (the CV of FMS was 4% - data not shown). The stability
tests indicated no signiﬁcant degradation of QC samples (accuracy
between 85 and 115% of the nominal concentration and precision
less than 15% - data not shown).3.2. Bioequivalence study
Two volunteers dropped-out, both for personal reasons, one
before the beginning of the study and other during the second in
house period. Therefore, forty-six volunteers completed the clinical
study. Tolerance of both tibolone formulations was good. General
physical examination, electrocardiogram and laboratory tests were
repeated at the end of the study and the results showed no relevant
alterations. The pharmacokinetic parameters found after a single
oral dose (3.75 mg) of each tibolone formulation (shown in Table 2)
were similar to those reported in the literature for postmenopausal
women. The mean 3a-hydroxytibolone plasma concentrations
versus time proﬁles of each tibolone formulation are shown in
Fig. 8. Table 3 summarizes the statistical analysis of Cmax, AUC(0-last)
and AUC(0-inf) individual test/reference ratios.4. Discussion
Pioneering studies on the in vivo humanmetabolism of tibolone
were based on liquid chromatography (LC) coupled to radioactivity
detection [9]. Later, a series of studies of the pharmacokinetics of
tibolone used a gas chromatography (GC) coupled to chemical
ionization MS (GC-CI-MS) method with 3a-hydroxytibolone-d5 as
I.S (LOQ: 0.1 ng/mL; retention times were not reported) [10e15].
Another GCmethod, coupled to electron impact high resolution MS
(GC-EI-HRMS), was developed. Ethisterone was employed as I.S
(LOQ: 0.02 ng/mL; retention time: approximately 11 min) [16]. At
last, a GC-MS method with 1,2-testosterone-d5 as I.S was devel-
oped (LOQ: 0.5 ng/mL; retention times were not reported) [17]. The
majority of the GC methods described above employed solid-phase
extraction and all of them used derivatization to increase the
volatility of the compounds of interest.
LC-MS and LC-MS/MS have become the most common tech-
niques employed for the quantiﬁcation of steroids in biological
matrices as an alternative to GC-MS, which has important limita-
tions. GC-MS, inwhich some compounds thermally decompose and
derivatization is often needed, has longer run times and it is not
suitable for conjugated steroids [18,19].
Table 4 summarizes the analytical details of the LC-MS and LC-
Fig. 6. Chromatogram at the limit of quantiﬁcation (LOQ) (top channel: 3a-hydroxytibolone/bottom channel: internal standard).
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Fig. 7. Carry-over evaluation: chromatogram at blank normal plasma run after an injection of a high concentration quality control (QCH) sample (top channel: 3a-hydroxytibolone/
bottom channel: internal standard).
Table 2
Pharmacokinetic parameters after the administration of both tibolone formulations.
Libiam™ Livolon
Cmax (ng/mL)
Mean 16.91 17.57
Range 7.92e31.70 5.78e37.50
Tmax (h)
Mean 1.61 1.48
Range 0.50e3.00 0.50e3.33
AUC(0-last) (ng.h/mL)
Mean 57.84 56.92
Range 19.64e93.79 24.18e101.01
AUC(0-inf) (ng.h/mL)
Mean 67.60 66.95
Range 22.12e110.38 27.87e114.98
ke (h1)
Mean 0.15 0.14
Range 0.07e0.64 0.06e0.59
t1/2 (h)
Mean 5.40 5.94
Range 1.09e9.35 1.17e12.04
Fig. 8. 3a-hydroxytibolone plasma mean concentrations versus time proﬁles of each
tibolone formulation.
Table 3
Summary of statistical analysis of Cmax, AUC(0-last) and AUC(0-inf) individual test/
reference ratios.
Ratio (%) 90% CI lower limit 90% CI upper limit
Cmax 104.26 97.48 111.51
AUC(0elast) 99.20 95.35 103.20
AUC(0einf) 100.07 96.42 103.86
L.A. Portela et al. / Analytical Chemistry Research 8 (2016) 16e25 23MS/MS methods employed for the determination of 3a-hydrox-
ytibolone so far [20e23]. In contrast to our method, all the liquid
chromatographic techniques mentioned employed p-toluene-
sulfonyl isocyanate derivatization to enhance the ionization process
because the ionization efﬁciencies of most steroids are relatively
low due to their apolar structure [24,25]. Previous attempts to
develop LC-MS or LC-MS/MS assays for 3a-hydroxytibolone quan-
tiﬁcation without derivatization shown practically no response in
negative ionization mode and low in positive ionization mode us-
ing either atmospheric pressure chemical ionization or electrospray
ionization [20,23].Despite their apolar structure, steroids can sometimes be
ionized with different ionization techniques using the adduct for-
mation approach [26,27]; the analyte (3a-hydroxytibolone) and I.S.
(3a-hydroxytibolone-d5) were detected mainly as ammonium ad-
ducts [MþNH4]þ (m/z 332.2 andm/z 337.4, respectively) that were
Table 4
Main data of the liquid chromatographic methods for 3a-hydroxytibolone quantiﬁcation in human plasma.
Zuo [20]
LC-MS
Ban [21]
LC-MS/MS
Shinde [22]
UPLC-MS/MS
Cardoso [23]
LC-MS/MS
Present method
LC-MS/MS
Tibolone dose 2.5 mg 5.0 mg 2.5 mg 2.5 mg 3.75 mg
Internal standard betamethasone 3aeOHetibolone-d6 3aeOHetibolone-d3 cyproterone 3aeOHetibolone-d5
Plasma volume 1000 mL 200 mL 500 mL 250 mL 900 mL
Extraction
technique
Liquid-liquid (ethyl acetate) Liquid-liquid (ethyl acetate) Liquid-liquid (ethyl acetate) Liquid-liquid
(chlorobutane)
Liquid-liquid (ethyl ether/hexane
and ammonium hydroxide/water)
Residue redissolved with
acetonitrile
Residue redissolved with
acetonitrile and sodium
sulfate
Residue redissolved with
acetonitrile
Residue
redissolved with
acetonitrile
Residue redissolved with mobile
phase
Followed by SPE (acetonitrile/
water)
Residue redissolved with
mobile phase
Derivatization p-toluenesulfonyl isocyanate p-toluenesulfonyl isocyanate p-toluenesulfonyl isocyanate p-toluenesulfonyl
isocyanate
None
Injection volume 80 mL 5 mL 10 mL 10 mL 20 mL
Mobile phase Gradient elution (ammonium
acetate/water and methanol)
Gradient elution (formic acid/
water and methanol/water)
Isocratic elution (methanol
and ammonium acetate/
water)
Isocratic elution
(acetonitrile/
water)
Isocratic elution (acetonitrile/water
and sodium hydroxide)
Flow rate 800 mL/min 250 mL/min 220 mL/min 800 mL/min 1150 mL/min
Column
speciﬁcations
200  4.6 mm (5 mm) 50  2.0 mm (3 mm) 100  2.1 mm (1.7 mm) 100  4.6 mm
(1.8 mm)
150  4.6 mm (5 mm)
Retention times
(analyte and
I.S.)
Approximately 6 and 5 min Approximately 5.5 and
5.3 min
Approximately 3.2 and 3.1 min Approximately 3.4
and 2.9 min
Approximately 2.5 and 2.5 min
Ionization
process
ESI ESI ESI APCI ESI
Monitoring
mode
SIM SRM MRM SRM MRM
LOQ 0.1 ng/mL 0.2 ng/mL 0.1 ng/mL 0.1 ng/mL 1 ng/mL
L.A. Portela et al. / Analytical Chemistry Research 8 (2016) 16e2524chosen as precursor ions for the MS/MS analysis. Signals were
inadequate without the ammonium hydroxide additive. In addi-
tion, a higher tibolone dose (3.75 mg) and a larger plasma volume
(900 mL) in comparison with the other liquid chromatographic
methods, resulted in adequate analyte concentration in the elec-
trosprayed solution. Lastly, the use of acetonitrile (solvent with low
surface tension) in themobile phase helped to achieve reproducible
electrospray and the total ﬂow rate was split in a 2:3 ratio to pre-
vent analyte saturation in the ESI process. The injection volumewas
able to retain the chromatographic performance of column even
after a large number of injections. Although a larger volume of
plasma was used, no matrix effect or carry-over was observed and
the hematological parameters of the volunteers showed no rele-
vant alterations at the end of the study. Sufﬁcient speciﬁcity was
achieved by efﬁcient chromatographic separation (relatively long
column) and multiple reaction monitoring (MRM).
Furthermore, derivatization is a time consuming procedure that
has some disadvantages including decreased precision due to the
added derivatization steps and possible hydrolysis of conjugates
whichwould affect the accuracy [28]. In addition, p-toluenesulfonyl
isocyanate is a costly reagent with well-known health hazards
(respiratory sensitisation, skin corrosion and serious eye irritation)
[29,30]. Finally, considering all the gas and liquid chromatographic
methods previously described, the LOQ ranged between 0.02 and
0.5 ng/mL. The LOQ (1 ng/mL) was adequate for the bioequivalence
assay, without derivatization or expensive UPLC equipment, and
the shortest retention times for 3a-hydroxytibolone and I.S. on
average makes it suitable for high sample throughput studies.5. Conclusion
The novel HPLC-MS/MS method described here for 3a-hydrox-
ytibolone quantiﬁcation in human plasma satisﬁes the re-
quirements of sensitivity, speciﬁcity and high sample throughputfor bioequivalence studies. Since the 90% CI for Cmax, AUC(0-last) and
AUC(0-inf) individual test/reference ratios were within the 80e125%
interval indicative of bioequivalence proposed by A.N.V.I.S.A. and
F.D.A., it is concluded that Livolon (1.25 mg tablet) provided by
Biolab Sanus Farmace^utica (Brazil) is bioequivalent to Libiam™
(1.25 mg tablet) produced by Libbs Farmace^utica (Brazil), with
regards to both rate and extent of absorption.Acknowledgements
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